CDK2 and non-small cell lung carcinoma: Roscovitine is a CDK2/7/9 inhibitor in clinical trials for the treatment of non-small cell lung cancer (NSCLC), Cushing’s disease, leukemia, multiple myeloma, HIV infection, herpes simplex infection, cystic fibrosis, and chronic inflammation disorders.